We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BRCA-Negative Results May Not Reduce Cancer Risk

By LabMedica International staff writers
Posted on 12 Dec 2013
Genetic changes in breast cancer genes are known to carry a higher risk, but even family members who test negative for the genetic differences are still at an increased probability of developing the disease. More...


The credence that a woman from a family with breast cancer gene (BRCA) mutations who tests negative for her family-specific BRCA mutation has the same chances of contracting the disease as someone in the general population has been challenged.

Scientists at the University of Manchester (UK) identified 807 BRCA families, including information about whether or not relatives had been tested. DNA was extracted from blood samples provided by women attending the genetic clinics. In addition to the BRCA1/2 mutation analysis, women were genotyped for 18 single nucleotide polymorphisms (SNPs) that have been shown to be associated with breast cancer risk in the general population and a subset of SNPs in familial breast cancer.

The investigators found that found that 49 women who had tested negative for the BRCA mutation had subsequently developed breast cancer. Even when the scientists factored in age, they found that in each age group, there were about twice as many cases of breast cancer as would be expected within the general population. Of the 49 women, 22 were among 279 women who tested negative from BRCA1 families, and 27 were among the 251 women who tested negative to BRCA2 mutations.

They also found that the women from BRCA1 families did not experience any increased risk, but the observed versus expected ratio (O/E) for women from BRCA2 families was 4.57 which led to the conclusion that BRCA-negative women from BRCA2 families face a fourfold increased risk of developing breast cancer.

Gareth R Evans, MD, FRCP, a professor and the lead author of the study said, “About 77 single nucleotide polymorphisms (SNPs), the genetic variations that can help track the inheritance of disease genes within families, are linked to breast cancer risk. Identification of additional SNPs is necessary to understand why some of the BRCA-negative women from BRCA families are at higher risk. If there is a strong family history of breast cancer in a BRCA2 family, for example with a mother and sister diagnosed under the age of 50, they should seek additional screening even if had tested negative previously.” The study was published on November 27, 2013, in the journal Cancer Epidemiology, Biomarkers & Prevention.

Related Links:

University of Manchester 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.